506260 Stock Overview
Anuh Pharma Limited manufactures and sells bulk drugs and chemicals in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Anuh Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹240.95 |
| 52 Week High | ₹265.00 |
| 52 Week Low | ₹86.00 |
| Beta | 0.59 |
| 1 Month Change | 11.68% |
| 3 Month Change | 47.06% |
| 1 Year Change | 167.93% |
| 3 Year Change | 70.40% |
| 5 Year Change | 265.63% |
| Change since IPO | 1,275.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506260 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.2% | -2.2% | -2.1% |
| 1Y | 167.9% | 55.3% | 45.3% |
Return vs Industry: 506260 exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: 506260 exceeded the Indian Market which returned 45.3% over the past year.
Price Volatility
| 506260 volatility | |
|---|---|
| 506260 Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 506260's share price has been volatile over the past 3 months.
Volatility Over Time: 506260's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 159 | Ritesh Shah | www.anuhpharma.com |
Anuh Pharma Limited manufactures and sells bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and intermediates. The company also provides corticosteroids, such as anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, and anti-histamines.
Anuh Pharma Limited Fundamentals Summary
| 506260 fundamental statistics | |
|---|---|
| Market cap | ₹12.03b |
| Earnings (TTM) | ₹543.23m |
| Revenue (TTM) | ₹6.40b |
22.2x
P/E Ratio1.9x
P/S RatioIs 506260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506260 income statement (TTM) | |
|---|---|
| Revenue | ₹6.40b |
| Cost of Revenue | ₹4.94b |
| Gross Profit | ₹1.46b |
| Other Expenses | ₹919.80m |
| Earnings | ₹543.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.84 |
| Gross Margin | 22.84% |
| Net Profit Margin | 8.48% |
| Debt/Equity Ratio | 3.2% |
How did 506260 perform over the long term?
See historical performance and comparison